Research
Hormonal
GLP-1 receptor agonists and endogenous GLP-1 provide cardiovascular protection by improving endothelial function, reducing blood pressure, and protecting the myocardium.
For individuals with Type 2 Diabetes or high cardiovascular risk, GLP-1 receptor agonists (like liraglutide or semaglutide) are not just glucose-lowering drugs but cardioprotective agents. They improve blood vessel function, lower blood pressure, and reduce the risk of major adverse cardiac events (heart attack, stroke, death).
StrongSupportsVERY_HIGH confidence
GLP-1 or GLP-1 receptor agonists have demonstrated multiple beneficial actions on the heart... long-term treatment with GLP-1 analogs reduces blood pressure... three CV outcome studies showed a significant reduction in a three-point MACE using liraglutide in LEADER, semaglutide in SUSTAIN-6, and recently dulaglutide in REWIND.
Why this rating
Cites large-scale, randomized, double-blind, placebo-controlled outcome trials (LEADER, SUSTAIN-6, REWIND).
Source
Incretin Hormones: The Link between Glycemic Index and Cardiometabolic Diseases
Teresa Salvatore et al. · Nutrients · 2019
DOI 10.3390/nu11081878
narrative_reviewCited 26×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Low glycemic index (GI) carbohydrates increase postprandial GLP-1 secretion and decrease GIP secretion compared to high GI carbohydrates, which mediates cardiometabolic health benefits.Moderate
- GIP (Glucose-dependent Insulinotropic Polypeptide) promotes fat storage and has unfavorable vascular effects, contrasting with the protective effects of GLP-1.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →